Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 13Other hematologic neoplasm 9Plasma cell 6Thoracic 1Other 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 90pembrolizumab 73Pemetrexed 66Cisplatin 56atezolizumab 31Paclitaxel 31Docetaxel 30durvalumab 28Specimen Handling 26Nivolumab 26Magnetic Resonance Spectroscopy 21osimertinib 20Gemcitabine 19130-nm albumin-bound paclitaxel 18Etoposide 17Cetuximab 16Radiotherapy 14Platinum 131,2-diaminocyclohexaneplatinum II citrate 11amivantamab 10Taxes 10Immunoglobulin G 10Radiation 9PM 01183 9Ipilimumab 9Disulfides 9Bevacizumab 9Topotecan 8lazertinib 7fludarabine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
auricularum × Thoracic × 30 days × Clear all
NCT05096663 2026-05-18

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2/3 Active not recruiting
82 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡